Show simple item record

dc.contributor.authorChui, Siu-Hon
dc.contributor.authorChan, Kelvin C.
dc.contributor.authorWong, Ricky N. S.
dc.contributor.authorChen, K.J.
dc.date.accessioned2008-01-08T15:14:59Z
dc.date.available2008-01-08T15:14:59Z
dc.date.issued2004
dc.identifier.citationMethods and Findings in Experimental and Clinical Pharmacology, 26(5): 349-355
dc.identifier.issn0379-0355
dc.identifier.doi10.1358/mf.2004.26.5.831326
dc.identifier.urihttp://hdl.handle.net/2436/15835
dc.descriptionMetadata only
dc.description.abstractChanges in serum homocysteine (Hcy), often related to stroke and vascular dementia, are negatively correlated with changes in serum insulin-like growth factor 1 (IGF-1) and growth hormone (GH) replacement decreases Hcy levels in men with GH deficiency. Very little information on the effects of Chinese medicines on GH and Hcy is available in the literature published in English. In this study, the effects of a Chinese medicine suppository, Vigconic VI-28 (VI-28), consisting of concentrated extracts of a composite mixture of herbal materials, on serum IGF-1 and Hcy were studied. In vivo observations after treatment with Chinese medicines have often indicated changes in biochemical profiles of measurable parameters related to those changes in endocrine secretions. Thirty six healthy males (age 47-66) were under observation over a 16-week schedule after using VI-28 suppository from 0 to 12 weeks. Blood specimens were taken monthly (except at the end of week 8) for analysis of Hcy and IGF-1 levels. Compared with week 0, IGF-1 levels (192.5 ± 66.4 ng/ml) were significantly elevated at week 4 (211.7 ± 80.5, p < 0.05) and week 12 (226.6 ± 95.2 ng/ml, p = 0.01). No significant changes were observed for Hcy for the whole cohort from week 0 to week 16. When the cohort was divided into 2 groups using a Hcy level of 13.0 µmol/l as the cut-off, a significant (p < 0.05) difference in IGF-1 was observed between the 2 groups at week 12 only. The mean IGF-1 of 14 subjects with higher Hcy levels was lower than that of the 22 subjects with lower Hcy. We believe that VI-28 may exert a regulatory effect on the relationship between Hcy and IGF-1, at least in subjects with relatively low levels of Hcy. In addition, we also observed an apparent association of hyperhomocysteinemia (Hcy greater than or equal to 13.0 mcmol/l) with decreased IGF-1.
dc.language.isoen
dc.publisherProus Science
dc.relation.urlhttp://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6X0P-4DCWC5R-1&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=2206b8c5c3f1ee0356d6fc4092f32d6b
dc.subjectSuppository
dc.subjectChinese medicine
dc.subjectVigconic VI-28
dc.subjectHomocysteine
dc.subjectInsulin-like growth factor 1
dc.subjectMen
dc.subjectAdult males
dc.titleA panel study on the effects of a Chinese medicinal suppository, Vigconic VI-28, on insulin-like growth factor 1 and homocysteine in healthy men
dc.typeJournal article
html.description.abstractChanges in serum homocysteine (Hcy), often related to stroke and vascular dementia, are negatively correlated with changes in serum insulin-like growth factor 1 (IGF-1) and growth hormone (GH) replacement decreases Hcy levels in men with GH deficiency. Very little information on the effects of Chinese medicines on GH and Hcy is available in the literature published in English. In this study, the effects of a Chinese medicine suppository, Vigconic VI-28 (VI-28), consisting of concentrated extracts of a composite mixture of herbal materials, on serum IGF-1 and Hcy were studied. In vivo observations after treatment with Chinese medicines have often indicated changes in biochemical profiles of measurable parameters related to those changes in endocrine secretions. Thirty six healthy males (age 47-66) were under observation over a 16-week schedule after using VI-28 suppository from 0 to 12 weeks. Blood specimens were taken monthly (except at the end of week 8) for analysis of Hcy and IGF-1 levels. Compared with week 0, IGF-1 levels (192.5 ± 66.4 ng/ml) were significantly elevated at week 4 (211.7 ± 80.5, p < 0.05) and week 12 (226.6 ± 95.2 ng/ml, p = 0.01). No significant changes were observed for Hcy for the whole cohort from week 0 to week 16. When the cohort was divided into 2 groups using a Hcy level of 13.0 µmol/l as the cut-off, a significant (p < 0.05) difference in IGF-1 was observed between the 2 groups at week 12 only. The mean IGF-1 of 14 subjects with higher Hcy levels was lower than that of the 22 subjects with lower Hcy. We believe that VI-28 may exert a regulatory effect on the relationship between Hcy and IGF-1, at least in subjects with relatively low levels of Hcy. In addition, we also observed an apparent association of hyperhomocysteinemia (Hcy greater than or equal to 13.0 mcmol/l) with decreased IGF-1.


This item appears in the following Collection(s)

Show simple item record